Document is current
Any future updates will be listed below
-
Authors
Diéguez-Martínez, Nora https://orcid.org/0000-0002-5366-4543
Espinosa-Gil, Sergio https://orcid.org/0000-0002-2873-8475
Yoldi, Guillermo
Megías-Roda, Elisabet https://orcid.org/0000-0001-7858-2168
Bolinaga-Ayala, Idoia https://orcid.org/0000-0002-6308-3646
Viñas-Casas, Maria https://orcid.org/0000-0003-1438-7325
Gorgisen, Gokhan https://orcid.org/0000-0001-6040-7863
Domingo-Ortí, Inés https://orcid.org/0000-0003-4959-4914
Pérez-Montoyo, Héctor https://orcid.org/0000-0002-9540-9604
Bayascas, Jose R. https://orcid.org/0000-0002-6096-2151
Colas, Eva https://orcid.org/0000-0003-0302-4828
Dolcet, Xavier https://orcid.org/0000-0003-1921-0449
Lizcano, Jose M. https://orcid.org/0000-0002-3154-5383
-
Funding
Funding for this research was provided by:
Ministerio de Economía y Competitividad (SAF2015-64237-R)
Ministerio de Ciencia e Innovación (PID2019-107561RB-I00)
European Regional Development Fund (SAF2015-64237-R, PID2019-107561RB-I00)
Universitat Autònoma de Barcelona
- License Information
-
More Information
Article History
Received: 23 May 2022
Revised: 20 August 2022
Accepted: 30 August 2022
First Online: 19 September 2022
Declarations
:
: Elisabet Megias-Roda and Héctor Pérez-Montoyo are Ability Pharmaceuticals employees; Jose M Lizcano serves as an uncompensated member of Ability Pharmaceuticals advisory board, and holds shares of the company.
: The animal study was approved by the Ethics Committee on Animal Experiments of the Universitat Autònoma de Barcelona (CEEAH) and the Ethics Commission in Animal Experimentation of the Generalitat de Catalunya, Spain.
: The use of samples from patients was approved by the Institutional Review Boards of Hospital Vall d’Hebron (Barcelona, Spain), and written informed consent was obtained from the patients involved.
: Not applicable.
